Physician profile
Scott E Schwartz
NPI 1821209065
$12,382.01
in general payments reported to CMS, 2019-2025
23 companies · $6,019 in 2025
The $6,019 reported for 2025 was more than what 86% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,884 · 2020: $125 · 2021: $121 · 2022: $143 · 2023: $279 · 2024: $811 · 2025: $6,019.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,500 · Food and Beverage: $1,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,500.00 |
| Food and Beverage | $1,609.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $9,947.86 | 2019-2025 | Azur Cx Detachable, Hydropearl, Glidewire |
| Boston Scientific Corporation | $881.03 | 2019-2024 | Embold Fibered |
| Bard Peripheral Vascular, INC. | $386.39 | 2019-2024 | Lutonix Drug Coated Balloon |
| Dendreon Pharmaceuticals LLC | $216.70 | 2024-2025 | Provenge |
| Ge Healthcare | $131.13 | 2019 | |
| Glaxosmithkline, LLC. | $121.10 | 2024 | Nucala |
| Biocompatibles, INC. | $104.93 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.81 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $87.30 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Progenics Pharmaceuticals, INC. | $70.02 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $46.79 | 2024-2025 | Gemtesa, Orgovyx |
| Philips North America LLC | $45.51 | 2023 | |
| Astellas Pharma US INC | $34.41 | 2025 | Xtandi |
| Cordis US Corp. | $25.71 | 2024 | Mynxgrip |
| Janssen Biotech, INC. | $25.24 | 2025 | Erleada |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $24.90 | 2025 | |
| Abbott Laboratories | $24.07 | 2020 | |
| Angiodynamics, INC. | $23.92 | 2024 | Nanoknife |
| Ekos Corporation | $23.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.90 | 2025 | Lynparza |
| Immunitybio, INC. | $16.44 | 2024 | |
| Tolmar, INC. | $13.29 | 2024 | |
| Abbvie INC. | $13.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.